




Lourdes A. Leon Guerrero
Governor
Joshua F. Tenorio
Lieutenant Governor

DEPARTMENT OF ADMINISTRATION
(DIPATTAMENTON ATMENESTRASION)
GENERAL SERVICES AGENCY
(Ufisinan Direktot)
Post Office Box 884 * Hagåtña, Guam 96932
TEL: (671) 475-1101/1250 * FAX: (671) 477-6788
GSA Fax: (671) 475-1727 or Email:
gsaprocurment@gsa.guam.gov.



Edward M. Birn
Director
Edith Pangelinan
Deputy Director

March 06, 2019

INVITATION FOR BID: GSA-011-19

MEDICATION

FOR: GUAM OPIOID RESPONSE PROJECT (GORP) 2018

AMENDMENT 2

1. Amend to replace pages 34 and 35 of 35 with the "Revised 3/06/19" page 34 and 35 of 35 (Attached)
2. Amend to change on page 3 of 35 under the "Invitation for Bid" the following:

From:

Required Delivery Date: 30 Days Upon Receipt of Purchase Order. For a period of one (1) year on an as needed basis upon availability of funds. This is an indefinite quantity bid.

To Now Read:

Required Delivery Date: 60 Days Upon Receipt of Purchase Order. For a period of one (1) year on an as needed basis upon availability of funds. This is an indefinite quantity bid.

3. Amend to change on page 4 of 35 "SPECIAL PROVISIONS" under "Delivery" the following:

From:


Delivery 30 Days Upon Receipt of Purchase. Delivery schedule time and quantity will be coordinated between the successful bidder and the requesting department on an as needed basis.

To Now Read:

Delivery: 60 Days Upon Receipt of Purchase Order. Delivery schedule time and quantity will be coordinated between the successful bidder and the requesting department on an as needed basis.

All others remain unchanged

Please Print	
ACKNOWLEDGEMENT COPY (Re-fax to GSA)	
Received By:	_____
Date:	_____
Company Name:	_____
Fax to: 475-1727 or 472-4217	
E-mail to: gsaprocurment@gsadoa.guam.gov	


CLAUDIA S. ACFALEE
Chief Procurement Officer

ITEM NO.	DESCRIPTION	QTY/UOM	UNIT PRICE	PRICE EXTENSION
1.1	Buprenorphine-Naloxone (14 bottles, 8mg/2mg) Expiration date no less than 18 months	250 ea.	\$ _____	\$ _____
2.1	Naltrexone (30 tabs/50mg) Expiration date no less than 18 months	40 ea.	\$ _____	\$ _____
3.1	Naloxone HCL Injection (2 ml 0.4mg/ml) Expiration date no less than 18 months	10 ea.	\$ _____	\$ _____
4.1	Buprenorphine (30 tabs/8mg) Expiration date no less than 18 months	250 ea.	\$ _____	\$ _____
5.1	Narcan Nasal Spray (2 units/4mg) Expiration date no less than 18 months	50 ea.	\$ _____	\$ _____
6.1	Naloxone HCL Injectable kits As per the following specifications:	50 ea.	\$ _____	\$ _____

Specifications:

To include 1 hard case, 2 (0.4 mg/1 ml) vials or ampoules (a small glass container) of naloxone, 2 safety-engineered Syringes with 25g, 1" needles attached, devices (known as "breakers," "snappers," or "openers") for opening ampoules safely, 1 rescue breathing barrier, 1 pair of non-latex gloves, 1 card that identifies the person who is trained to give the naloxone. Expiration date no less than 18 months

Bidding ON/Remarks:

7.1	Naloxone Spray kits As per the following specifications:	10 ea.	\$ _____	\$ _____
-----	---	--------	----------	----------

Specifications:

To include 1 hard case, 2 doses of Narcan® Nasal Spray (4 mg/0.1ml), 1 rescue breathing barrier, 1 pair of non-latex gloves, 1 card that identifies the person who is trained to give the naloxone, 1 insert with instructions (English and French), 1 insert with additional information on the medication (English and French). Expiration date no less than 18 months

Bidding ON/Remarks:

GENERALS:

ALL PHARMACEUTICAL PRODUCTS MUST:

- a. meet the requirements of manufacturing legislation and regulation of pharmaceuticals and medical products;
- b. conform to all the specifications contained herein;
- c. be certified by a competent authority;
- d. indicate the dates of manufacture and expiry;
- e. have remaining shelf life of at least 80% of the total stipulated shelf life at the time of manufacture;
- f. on request, make available samples and studies showing bioavailability and stability, especially stability under conditions of high temperature and humidity.
- g. prove the Quality of packing and the appearance of labels through representative samples on request.

PRODUCT INFORMATION:

The following information will be required, when applicable, for each product offered by the Bidder:

- generic name or INN (International Non-propriety Name)
- presentation, strength, quantity in each container
- country of origin, name and address of the Manufacturer
- Pharmacopoeia or other applicable compendia standards
- proper documentation of Quality assurance
- shelf life
- type of container
- Failure to include any of this information may, at the discretion of the Purchaser, disqualify the bid.

LABELLING:

The language of the labels should strictly be English. The label for each pharmaceutical product shall meet standards and include:

- the INN or generic name prominently displayed
- the active ingredient per unit, dose, tablet or capsule, etc. (strength & presentation)
- the applicable pharmacopoeia standard
- the Purchaser's logo and code number if required
- content per container
- instructions for use (only on instructions by the purchaser)
- special storage requirements
- batch number
- date of manufacture and date of expiry.
- name and address of Manufacturer
- country of origin
- "Keep out of reach of children"
- The outer carton should also display the above information.

PHARMACEUTICAL PACKING:

Containers for Pharmaceuticals must conform with recognized Pharmacopoeia Standards.

The size of the container should be proportional to its content.
Containers should be tamper-proof.
Ampoules should be one ended and auto-breakable.

NOTE:

These specifications have been written to describe minimum requirements to be supplied the vendor.
The successful bidder shall furnish all necessary and desirable information instructions for proper prescription.

The government reserves the right to accept and/or reject any and all bids, to waive any defects, irregularities, or specification discrepancies and to award the bid as council deems to be in the best interest of the government.

Partial deliveries will not be accepted. All requirements specified must be provided at time of delivery.
Bidder shall identify on their bids any deviations from requirement on remarks column and state item being offered to evaluation processing. Failure to comply may result in rejection of bid.

These opioid response medications specifications were developed by the Project Director of the Guam Opioid Response Project, Drug & Alcohol Services and a Staff Psychiatrist and

Approved by: ABNER P. PASATIEMPO, Staff Psychiatrist, Professional Support Unit;
ATHENA M. DUENAS, Supervisor Drug & Alcohol Services
REY M. VEGA, Director, Guam Behavioral Health & Wellness Center